Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80211
Name nodal marginal zone lymphoma
Definition A marginal zone B-cell lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma marginal zone lymphoma nodal marginal zone lymphoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03322865 Phase II Obinutuzumab Obinutuzumab in Marginal Zone Lymphoma Active, not recruiting DEU 0
NCT03474744 Phase II Copanlisib + Rituximab Copanlisib and Rituximab in Marginal Zone Lymphoma Patients Active, not recruiting DEU | AUT 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03697512 Phase II Ibrutinib + Rituximab MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU) Active, not recruiting ITA | FRA | BEL 2
NCT04223765 Phase I Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma Recruiting USA 0
NCT04680052 Phase III Lenalidomide + Rituximab Lenalidomide + Rituximab + Tafasitamab-cxix A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT04728893 Phase II ARQ 531 Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | AUS 4
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT06006117 Phase III Lenalidomide + Rituximab Lenalidomide + Mosunetuzumab-axgb Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma Recruiting FRA 0
NCT06350318 Phase II Rituximab + Zanubrutinib Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas Recruiting USA 0
NCT06378190 Phase Ib/II TranspoCART19 Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) Recruiting ESP 0